Uncertainty for middle-market companies has bled into the decision-making process, says Tom McGee, national managing partner of Deloitte Growth Enterprise Services at Deloitte & Touche LLP. However, McGee adds that companies have done a good job managing within that uncertain space. The Deal Pipeline caught up with McGee at the 11th annual Yale School of Management Private Equity Conference, where he also discussed middle-market companies' love affair with investing in technology, as well as trends in the midmarket space involving BRICs. - Sarah Hashim-Waris
Three directors are leaving Valeant Pharmaceuticals International's board, including Warburg Pincus' Fred Hassan, ValueAct's G. Mason Morfit and Persistence Capital's Lloyd M. Segal. For other updates launch today's Movers & shakers slideshow.